Rhopressa logo
MENU CLOSE

Dosing & Safety

The consistency and tolerability of Rhopressa® could give your patients the unique care they need.1

Confidence in consistency

Unlike beta blockers or alpha agonists,
Rhopressa® delivers:

  • Decreased treatment burden with once-daily dosing2,3
  • 24-hour IOP control with one drop4
  • Consistent 20% IOP reduction regardless of baseline pressure1,5
  • No systemic side effects or contraindications2

Rhopressa® has no contraindications, unlike beta blockers, alpha agonists, or CAIs4

Rhopressa® may be a preferred choice for patients with comorbidities, such as heart disease, diabetes, or depression.3

Which patients are right for Rhopressa®?

  • PATIENTS WHO NEED ADDITIONAL IOP REDUCTION

    Whether on a PGA monotherapy or multiple therapies1

  • PATIENTS WITH LOW BASELINE PRESSURES

    Whether low-tension or low-treated baseline pressure6

  • PATIENTS WITH COMORBIDITIES

    Rhopressa® may be the preferred choice for patients with systemic conditions like heart disease, diabetes, or depression3

Administration notes2

Rhopressa® requires one drop of medication per day and should be taken in the evening.

If one dose is missed, treatment should continue with the next dose in the evening.

Twice-a-day dosing is not well tolerated and is not recommended.

If Rhopressa® is to be used concomitantly with other topical ophthalmic products, administer each drug product at least 5 minutes apart.

Store Rhopressa® in the refrigerator (36 ° to 46 °F) until opened. After opening, Rhopressa® may be kept at 36 ° to 77 °F for up to 6 weeks. If after opening the product is kept refrigerated at 36 ° to 46 °F, then the product can be used until the expiration date stamped on the bottle.

ROCKET 1, 2, and 4

Once-daily Rhopressa® exhibited a safe, tolerable performance1,2

Tolerability of Rhopressa® was studied in >1,400 patients with OAG or OHT during 3 different Phase 3 studies.6,7

In clinical studies for Rhopressa®, ocular adverse events (AEs) were mild and tolerable1

  • 53% of patients experienced hyperemia while taking Rhopressa®2
  • Other ocular AEs in ∼20% of patients included cornea verticillata, instillation site pain, and conjunctival hemorrhage2
  • 6% of patients discontinued therapy due to conjunctival hyperemia2

Talk to your patients about what to expect with Rhopressa®

  • TREATMENT SUCCESS BEGINS WITH PATIENT EDUCATION
  • Recommend Rhopressa® to your patients with full confidence
  • 89%

    of patients reported Rhopressa® was tolerated “well” or better in a survey1

  • 73%

    of physician-rated patient acceptance was good or excellent8

  • Be in the know about hyperemia

    • ROCK inhibitors may cause vasodilation on the ocular surface5
    • 53% of patients experienced hyperemia in clinical studies; however, only 6% of patients discontinued for this reason2
  • What patients should know about hyperemia

    • Rhopressa® causes blood vessels in the eye to dilate, which may result in visible redness5
    • Redness caused by this treatment is not an allergy or an inflammation5

Remind your patients

  • Rhopressa® should be taken once daily at night2
  • Patients should not stop taking their medication without speaking to you first2

View Savings

Help your patients save on
Rhopressa®

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Bacterial Keratitis: There have been reports of bacterial keratitis associated with the use of multiple-dose containers of topical ophthalmic products. These containers had been inadvertently contaminated by patients who, in most cases, had a concurrent corneal disease or a disruption of the ocular epithelial surface.

Contact Lenses: Contact lenses should be removed prior to instillation of Rhopressa® and may be inserted 15 minutes following its administration.

ADVERSE REACTIONS

The most common ocular adverse reaction observed in controlled clinical studies with Rhopressa® dosed once daily was conjunctival hyperemia, reported in 53% of patients. Six percent of patients discontinued therapy due to conjunctival hyperemia. Other common (approximately 20%) adverse reactions were: corneal verticillata, instillation site pain, and conjunctival hemorrhage. Instillation site erythema, corneal staining, blurred vision, increased lacrimation, erythema of eyelid, and reduced visual acuity were reported in 5-10% of patients.

The corneal verticillata seen in Rhopressa®- treated patients were first noted at 4 weeks of daily dosing. This reaction did not result in any apparent visual functional changes. Most corneal verticillata resolved upon discontinuation of treatment.

Please click here for full prescribing information for Rhopressa®.

You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

INDICATIONS AND USAGE

Rhopressa® (netarsudil ophthalmic solution) 0.02% is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

DOSAGE AND ADMINISTRATION

The recommended dosage is one drop in the affected eye(s) once daily in the evening.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Bacterial Keratitis: There have been reports of bacterial keratitis associated with the use of multiple-dose containers of topical ophthalmic products. These containers had been inadvertently contaminated by patients who, in most cases, had a concurrent corneal disease or a disruption of the ocular epithelial surface.

Contact Lenses: Contact lenses should be removed prior to instillation of Rhopressa® and may be inserted 15 minutes following its administration.

ADVERSE REACTIONS

The most common ocular adverse reaction observed in controlled clinical studies with Rhopressa® dosed once daily was conjunctival hyperemia, reported in 53% of patients. Six percent of patients discontinued therapy due to conjunctival hyperemia. Other common (approximately 20%) adverse reactions were: corneal verticillata, instillation site pain, and conjunctival hemorrhage. Instillation site erythema, corneal staining, blurred vision, increased lacrimation, erythema of eyelid, and reduced visual acuity were reported in 5-10% of patients.

The corneal verticillata seen in Rhopressa®- treated patients were first noted at 4 weeks of daily dosing. This reaction did not result in any apparent visual functional changes. Most corneal verticillata resolved upon discontinuation of treatment.

Please click here for full prescribing information for Rhopressa®.

You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

INDICATIONS AND USAGE

Rhopressa® (netarsudil ophthalmic solution) 0.02% is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

DOSAGE AND ADMINISTRATION

The recommended dosage is one drop in the affected eye(s) once daily in the evening.

References:

  1. Zaman F, Gieser SC, Schwartz GF, Swan C, Williams JM. A multicenter, open-label study of netarsudil for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension in a real-world setting. Curr Med Res Opin. 2021;37(6):1011-1020.
  2. Rhopressa® (netarsudil ophthalmic solution) 0.02% Prescribing Information, Aerie Pharmaceuticals, Inc., Irvine, Calif. 2019.
  3. Robin A, Grover DS. Compliance and adherence in glaucoma management. Indian J Ophthalmol. 2011;59 Suppl(Suppl1):S93-6.
  4. Peace JH, McKee HJ, Kopczynski CC. A randomized, phase 2 study of 24-h efficacy and tolerability of netarsudil in ocular hypertension and open-angle glaucoma. Ophthalmol Ther. 2021;10(1):89-100.
  5. Singh IP, Fechtner RD, Myers JS, et al. Pooled efficacy and safety profile of netarsudil ophthalmic solution 0.02% in patients with open-angle glaucoma or ocular hypertension. J Glaucoma. 2020;29(10):878-884.
  6. Serle JB, Katz LJ, McLaurin E, et al. Two phase 3 clinical trials comparing the safety and efficacy of netarsudil to timolol in patients with elevated intraocular pressure: Rho Kinase Elevated IOP Treatment Trial 1 and 2 (ROCKET-1 and ROCKET-2). Am J Ophthalmol. 2018;186:116-127.
  7. Khouri AS, Serle JB, Bacharach J, et al. Once-daily netarsudil versus twice-daily timolol in patients with elevated intraocular pressure: the randomized phase 3 ROCKET-4 study. Am J Ophthalmol. 2019;204:97-104.
  8. Data on file, Aerie Pharmaceuticals, Inc.
X

You are now leaving Rhopressa.com/hcp

Continue

Cancel